Crossmark Global Holdings Inc. Grows Position in Haleon plc (NYSE:HLN)

Crossmark Global Holdings Inc. raised its holdings in shares of Haleon plc (NYSE:HLN - Free Report) by 55.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 480,760 shares of the company's stock after buying an additional 171,877 shares during the quarter. Crossmark Global Holdings Inc.'s holdings in Haleon were worth $5,087,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. Clearbridge Investments LLC raised its position in shares of Haleon by 8.6% during the 2nd quarter. Clearbridge Investments LLC now owns 41,753,987 shares of the company's stock valued at $344,888,000 after buying an additional 3,307,009 shares in the last quarter. Sculptor Capital LP increased its position in shares of Haleon by 67.8% during the 2nd quarter. Sculptor Capital LP now owns 8,887,098 shares of the company's stock valued at $73,407,000 after purchasing an additional 3,592,000 shares during the last quarter. Douglas Lane & Associates LLC raised its holdings in shares of Haleon by 1.6% during the 2nd quarter. Douglas Lane & Associates LLC now owns 8,533,768 shares of the company's stock valued at $70,489,000 after buying an additional 131,892 shares in the last quarter. Envestnet Asset Management Inc. lifted its position in Haleon by 2.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 7,572,548 shares of the company's stock worth $62,549,000 after buying an additional 196,843 shares during the last quarter. Finally, Martin Investment Management LLC boosted its stake in Haleon by 12,018.4% in the first quarter. Martin Investment Management LLC now owns 4,463,205 shares of the company's stock worth $37,893,000 after buying an additional 4,426,375 shares in the last quarter. 6.67% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. UBS Group raised shares of Haleon to a "strong-buy" rating in a report on Tuesday, October 1st. The Goldman Sachs Group cut Haleon from a "buy" rating to a "neutral" rating in a report on Tuesday, August 6th. Berenberg Bank started coverage on Haleon in a research report on Tuesday, August 6th. They issued a "buy" rating for the company. Finally, Morgan Stanley lifted their price target on Haleon from $9.90 to $10.95 and gave the company an "overweight" rating in a research report on Friday, September 20th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, Haleon has a consensus rating of "Buy" and an average price target of $10.95.

Haleon Stock Down 2.5 %

NYSE:HLN traded down $0.24 on Tuesday, reaching $9.27. 4,104,471 shares of the stock traded hands, compared to its average volume of 5,226,127. The company's fifty day simple moving average is $10.18 and its 200 day simple moving average is $9.32. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $41.96 billion, a price-to-earnings ratio of 27.97, a PEG ratio of 2.90 and a beta of 0.30.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.